Jag Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Jag Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-262	Closed	-$216K	–	181
2023 Q3	$216K	Buy	+262	New	+$206K	0.03%	160
2023 Q1	–	Sell	-6,424	Closed	-$4.63M	–	192
2022 Q4	$4.63M	Buy	+6,424	New	+$4.74M	0.67%	35
2016 Q1	–	Sell	-34,373	Closed	-$18.7M	–	105
2015 Q4	$18.7M	Sell	34,373 -1,874	-5%	-$1.02M	3.49%	7
2015 Q3	$16.9M	Buy	36,247 +357	+1%	+$192K	3.2%	13
2015 Q2	$17.2M	Buy	35,890 +827	+2%	+$404K	3.14%	10
2015 Q1	$15.8M	Sell	35,063 -350	-1%	-$148K	2.84%	13
2014 Q4	$14.5M	Buy	35,413 +228	+0.6%	+$89.7K	2.67%	18
2014 Q3	$12.7M	Buy	35,185 +12,782	+57%	+$4.28M	2.55%	16
2014 Q2	$6.33M	Buy	22,403 +31	+0.1%	+$9.19K	1.23%	32
2014 Q1	$6.72M	Sell	22,372 -23,684	-51%	-$7.3M	1.37%	31
2013 Q4	$12.7M	Buy	46,056 +13,825	+43%	+$3.98M	2.53%	13
2013 Q3	$10.1M	Buy	32,231 +16,689	+107%	+$4.39M	2.23%	19
2013 Q2	$3.5M	Buy	+15,542	New	+$3.62M	0.85%	39

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jag Capital Management's REGN Position: Q4 2023 in Review

Jag Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 262 shares — an estimated $216K sold.

Jag Capital Management first reported a position in REGN in Q2 2013 and held it in 13 quarters. The position peaked at $18.7M in Q4 2015. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Jag Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Jag Capital Management sold 262 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $216K.
Jag Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Jag Capital Management's Regeneron Pharmaceuticals position peaked at $18.7M in Q4 2015.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Jag Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.